Abstract
The prevalence and the factors related to cytomegalovirus (CMV) disease (CMVd) during the 1st year of renal transplantation (RTx) and the relationship between CMVd and early and long-term graft and RTx-patient (RTx-p) survival were evaluated. In 505 RTx-p, followed up for 8(5–11) years, data were recorded after 1-(T1) and 12-(T12) months of RTx. CMVd was defined either by CMV replication without clinical signs of disease (CMVr, 43%), or CMV replication with signs of disease (CMVs, 57%). During the 1st year of RTx, 45% of RTx-p had CMVd (CMVd+). CMVd+ patients were older than CMVd− patients. Female gender and Donor CMV-IgG+ (CMV IgG−D+)/recipient IgG- (CMV IgG−R-) status were more prevalent in CMVd+. At T1, CMVd+ had lower albumin, haemoglobin, and higher uric-acid and reactive C-protein than CMVd− and, at T1 and T12, received more steroids. Albumin-T1 was the unique factor in determining CMVd+, maintaining its significance also after the inclusion of IgG−D+/IgG−R− status to the model. CMVs had higher prevalence of CMV IgG-D+/IgG-R- than CMVr. CMVd, CMVr, and CMVs had no impact on graft loss (11% of RTx-p) and RTx-p death (8% of RTx-p). CMVd is highly prevalent during the 1st year of RTx. Albumin-T1 influences CMVd insurgence. CMVd did not impact on RTx and RTx-p loss.
Highlights
IntroductionThe prevalence of chronic kidney disease (CKD) has increased in recent years and renal transplantation (RTx) is considered the best therapy
In the work presented by Witzcke et al, in which 296 RTx-p were studied, the prevalence of CMVd and CMV replication (CMVr) was of 51% and 75%, respectively [12]
From the analyses presented in our work, CMVd, CMVr, and CMVs showed no significant association with the major clinical outcomes evaluated
Summary
The prevalence of chronic kidney disease (CKD) has increased in recent years and renal transplantation (RTx) is considered the best therapy. RTx patients (RTx-p) are characterized by a high risk of complications, partly related to their clinical characteristics and to therapies prescribed during the RTx. Despite this, RTx patients (RTx-p) are characterized by a high risk of complications, partly related to their clinical characteristics and to therapies prescribed during the RTx In this scenario, infectious diseases have a strong impact on graft and patient survival [1,2,3]. Cytomegalovirus (CMV) disease has a high prevalence in RTx-p, especially during the first year of RTx, ranging between 10% and 42% [4,5]. CMV disease (CMVd) may be classified according to the presence of clinical and biochemical signs in: asymptomatic.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
